Alzheimer’s Drug Is Bonanza for Biogen, Most Likely at Taxpayer Expense

The Food and Drug Administration’s decision on Monday to approve a new Alzheimer’s medication over the fierce objections of its scientific advisers sets into motion one of the most controversial drug introductions in years.